Clinical Trials
16 trialsNCT03899155 2026-06-03
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2 Recruiting
NCT03768063 2026-04-28
IMbrella B
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT02483247 2023-11-14
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT01636908 2021-04-15
ICK
Amsterdam UMC, location VUmc
Phase NA Completed
NCT01190241 2020-11-20
TSAP
Amsterdam UMC, location VUmc
Phase NA Terminated
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT00463060 2018-07-18
Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT01020630 2014-05-14
SUN-CASE
Johannes Gutenberg University Mainz
Phase 2 Completed
NCT00402415 2013-12-18
Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy
Yale University
Phase 1 Terminated
NCT00443534 2013-05-24
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Pfizer
Phase NA Completed
NCT01548170 2012-03-08
To Assess the Interaction Between Sunitinib and Ketoconazole to Reduce the Dose and Cost of Sunitinib
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Phase 1 Completed
NCT00732992 2011-03-17
A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies
Pfizer
Phase 1 Completed
NCT00615446 2010-04-30
A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT00511849 2010-02-17
Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT00137423 2009-09-30
Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer
Pfizer
Phase 2 Completed